Artal Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Artal Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-350,000	Closed	-$16M	–	148
2017 Q4	$16M	Buy	350,000 +150,000	+75%	+$7.48M	0.24%	36
2017 Q3	$8.97M	Buy	200,000 +150,000	+300%	+$5.11M	0.15%	49
2017 Q2	$1.5M	Hold	50,000	–	–	0.03%	100
2017 Q1	$1.11M	Sell	50,000 -50,000	-50%	-$1.07M	0.02%	87
2016 Q4	$1.89M	Hold	100,000	–	–	0.04%	79
2016 Q3	$3M	Buy	100,000 +50,000	+100%	+$1.56M	0.06%	75
2016 Q2	$1.92M	Sell	50,000 -50,000	-50%	-$2.08M	0.04%	60
2016 Q1	$3.81M	Buy	+100,000	New	+$3.48M	0.07%	44

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Artal Group's JUNO Position: Q1 2018 in Review

Artal Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 100,000 shares — an estimated $4.57M sold.

Artal Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $10.1M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Artal Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Artal Group sold 100,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $4.57M.
Artal Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
Artal Group's Juno Therapeutics, Inc. position peaked at $10.1M in Q2 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.